Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
Journal Title: Nasza Dermatologia Online - Year 2015, Vol 6, Issue 2
Abstract
Biologic drugs have been recently used to treat psoriasis. However, some patients do not respond or lose therapeutic benefit with first-line use of tumor necrosis factor (TNF) antagonists. We report a case of psoriasis vulgaris, that failed to respond to TNF antagonists, infliximab and adalimumab, completely disappeared after treatment with ustekinumab, a therapeutic agent for biologically blocking p40 protein of interleukin (IL) 12 and 23. This report highlights anti-TNF agents only inhibited the TNF-α/inducible nitric oxide synthase (iNOS)-producing dendritic cells (TIP-DCs), but the plasmacytoid-DC-derived psoriatic response was re-initiated. On the other hand, ustekinumab may inhibit both the TIP-DCs and the plasmacytoid-DC-derived inflammatory response
Authors and Affiliations
Chiharu Tateishi,, Kulsupa Nimmannitya, Hisayoshi Imanishi, Daisuke Tsuruta
Keywords
Related Articles
- EP ID EP132610
- DOI 10.7241/ourd.20153.79
- Views 89
- Downloads 0
Blahoslav Bednar (1916-1998) i guz, który nosi jego imię
Beer induced angioedema – A case report
Beer is a popular alcoholic beverage consumed all over the world. Type I hypersensitivity reactions like urticaria and anaphylaxis due to beer have been reported very infrequently in the literature. We report a case of...
komentarz: Nerwiakowłókniak splotowaty w obrębie twarzy u pacjenta z neurofibromatozą typu I: opis przypadku
Sarna noruega en un paciente inmunodeprimido [Norwegian scabies in an immunocompromised patient]
-
Tasleem's water jet sign - A new sign in dermatology